Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

1134299

USP

Citalopram Related Compound F

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

(RS)-Dimethyl(1-methyl-3,3-diphenylallyl)amine hydrochloride

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H21N · HCl
Numéro CAS:
55011-89-7
Poids moléculaire :
287.83
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

citalopram

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

InChI

1S/C18H21N.ClH/c1-15(19(2)3)14-18(16-10-6-4-7-11-16)17-12-8-5-9-13-17;/h4-15H,1-3H3;1H

Clé InChI

ZVTAYVQUGPGRAF-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Citalopram Related Compound F USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Citalopram Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1134233

Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard

1134244

Citalopram Related Compound A, United States Pharmacopeia (USP) Reference Standard

1134222

Citalopram Related Compound H, United States Pharmacopeia (USP) Reference Standard

1134197

Citalopram Related Compound G, United States Pharmacopeia (USP) Reference Standard

1134288

Citalopram Related Compound E, United States Pharmacopeia (USP) Reference Standard

1134266

Citalopram Related Compound C, United States Pharmacopeia (USP) Reference Standard

1134255

Citalopram Related Compound B, United States Pharmacopeia (USP) Reference Standard

1134277

Citalopram Related Compound D, United States Pharmacopeia (USP) Reference Standard

Y0000855

Citalopram for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001008

Citalopram hydrobromide, European Pharmacopoeia (EP) Reference Standard

Y0001007

Citalopram hydrochloride, European Pharmacopoeia (EP) Reference Standard

PHR1640

Citalopram Hydrobromide, Pharmaceutical Secondary Standard; Certified Reference Material

1134142

R-Citalopram oxalate, United States Pharmacopeia (USP) Reference Standard

PHR1906

Citalopram Related Compound H, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1902

Citalopram Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1904

Citalopram Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1903

Citalopram Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

BP1153

Citalopram hydrobromide, British Pharmacopoeia (BP) Reference Standard

PHR1905

Citalopram Related Compound G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1901

Citalopram Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1154

Citalopram impurity standard, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Conseils de prudence

P301 + P310

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

B Ebert et al.
Pharmacology & toxicology, 82(3), 157-160 (1998-04-29)
The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketobemidone and a spasmolytic compound, (RS)-3-dimethylamino-1,1-diphenylbut-1-ene, hydrochloride (A29), in a one to five ratio. Using
Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.
N Grosman
Acta pharmacologica et toxicologica, 50(1), 78-80 (1982-01-01)
J C Raeder et al.
Acta anaesthesiologica Scandinavica, 30(7), 502-506 (1986-10-01)
A double-blind comparison of the effect of Ketogan (ketobemidone and A-29, an anticholinergic and spasmolytic agent) and morphine + scopolamine as premedication was performed in 113 women admitted for abortion and in 114 women admitted for gynaecological dilatation and curettage.
P Anderson et al.
European journal of clinical pharmacology, 19(3), 217-223 (1981-02-01)
The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intravenous administration of Ketogin 2 ml, containing ketobemidone chloride 10 mg, and a spasmolytic compound N,N-dimethyl-3,3-diphenyl-1-methylallylamine
M Kjaer et al.
Acta oncologica (Stockholm, Sweden), 27(5), 583-589 (1988-01-01)
Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan tablets and mixture. The
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique